Journal Watch · Frontiers in Immunology · 2026
Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder.
These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.
TL;DR
These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.
Key findings
- Compared to the mild group, the severe group had higher age, a higher male ratio, and higher cerebrospinal fluid protein levels (p=0.004, p=0.017, p<0.001, respectively).
- Cerebrospinal fluid levels of TIM-3, galectin-9, and IL-2Rα were significantly higher in the severe group (p=0.011, p=0.008, p=0.006, respectively), with area under the ROC curve values of 0.89, 0.88, and 0.80, respectively.<h4>Conclusion</h4>In AQP4-IgG-positive NMOSD patients, elevated levels of TIM-3, galectin-9, and IL-2Rα in CSF during the acute attack phase correlate with worsening disability severity at 6 months.
- These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
These molecules were measured in the soluble fraction. Disease severity at 6 months was classified as mild (EDSS < 6) or severe (EDSS ≥ 6). ROC analysis was performed to evaluate prognostic performance.<h4>Results</h4>Twenty-six cases of NMOSD showed mild disability, and 8 cases showed severe disability. All cases of MOGAD showed mild disability.
Full abstract (original)
Background: <h4>Background</h4>Neuromyelitis optica spectrum disorders (NMOSD) are severe autoimmune diseases of the central nervous system characterized by autoantibodies against aquaporin 4 (AQP4-IgG). Despite the availability of several molecular targeted therapies, biomarkers capable of predicting subsequent disability early during the acute relapse phase remain insufficient. Given that abnormalities in immune checkpoint molecules are known to be involved in autoimmunity, this study investigated whether immune checkpoint-related molecules in the cerebrospinal fluid (CSF) of acute-phase AQP4-IgG-positive NMOSD patients correlate with disability at 6 months.<h4>Methods</h4>Thirty-four patients with AQP4 IgG-positive NMOSD, 10 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)at disease flare, and 11 patients with idiopathic normal pressure hydrocephalus (iNPH) as control non-inflammatory neurological disease were enrolled. Bead-based multiplex assays were used to quantify levels of immune checkpoint molecules and related factors (PD-1, PD-L1, CTLA-4, TIM-3, galectin-9, LAG-3, 4-1BB, B7.2, IL-2Rα, TGF-β1, FasL) in CSF.
What they did: These molecules were measured in the soluble fraction. Disease severity at 6 months was classified as mild (EDSS < 6) or severe (EDSS ≥ 6). ROC analysis was performed to evaluate prognostic performance.<h4>Results</h4>Twenty-six cases of NMOSD showed mild disability, and 8 cases showed severe disability. All cases of MOGAD showed mild disability.
Results & conclusions: Compared to the mild group, the severe group had higher age, a higher male ratio, and higher cerebrospinal fluid protein levels (p=0.004, p=0.017, p<0.001, respectively). Cerebrospinal fluid levels of TIM-3, galectin-9, and IL-2Rα were significantly higher in the severe group (p=0.011, p=0.008, p=0.006, respectively), with area under the ROC curve values of 0.89, 0.88, and 0.80, respectively.<h4>Conclusion</h4>In AQP4-IgG-positive NMOSD patients, elevated levels of TIM-3, galectin-9, and IL-2Rα in CSF during the acute attack phase correlate with worsening disability severity at 6 months. These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1923404 · PubMed 42898123.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
These findings suggest their potential as early prognostic biomarkers, which requires validation in a large cohort.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. These molecules were measured in the soluble fraction.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1923404. PubMed ID: 42898123. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/soluble-tim-3-and-galectin-9-in-cerebrospinal-fluid-are-associated-with-923404/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides